HomeCompareCJJD vs ARCC

CJJD vs ARCC: Dividend Comparison 2026

CJJD yields 131.58% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CJJD wins by $13.09M in total portfolio value
10 years
CJJD
CJJD
● Live price
131.58%
Share price
$1.52
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13.11M
Annual income
$5,254,291.38
Full CJJD calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — CJJD vs ARCC

📍 CJJD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCJJDARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CJJD + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CJJD pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CJJD
Annual income on $10K today (after 15% tax)
$11,184.21/yr
After 10yr DRIP, annual income (after tax)
$4,466,147.67/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, CJJD beats the other by $4,466,146.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CJJD + ARCC for your $10,000?

CJJD: 50%ARCC: 50%
100% ARCC50/50100% CJJD
Portfolio after 10yr
$6.57M
Annual income
$2,627,146.27/yr
Blended yield
40.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

CJJD
No analyst data
Altman Z
1.4
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CJJD buys
0
ARCC buys
0
No recent congressional trades found for CJJD or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCJJDARCC
Forward yield131.58%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$13.11M$24.5K
Annual income after 10y$5,254,291.38$1.16
Total dividends collected$12.01M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CJJD vs ARCC ($10,000, DRIP)

YearCJJD PortfolioCJJD Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$23,858$13,157.89$11,381$541.15+$12.5KCJJD
2$54,866$29,338.29$12,621$284.08+$42.2KCJJD
3$121,763$63,055.65$13,827$145.31+$107.9KCJJD
4$261,068$130,782.22$15,062$73.43+$246.0KCJJD
5$541,406$262,062.65$16,364$36.89+$525.0KCJJD
6$1,087,218$507,914.03$17,757$18.49+$1.07MCJJD
7$2,116,559$953,235.83$19,258$9.25+$2.10MCJJD
8$3,999,043$1,734,324.47$20,880$4.63+$3.98MCJJD
9$7,341,448$3,062,472.67$22,636$2.32+$7.32MCJJD
10$13,109,641$5,254,291.38$24,539$1.16+$13.09MCJJD

CJJD vs ARCC: Complete Analysis 2026

CJJDStock

China Jo-Jo Drugstores, Inc., together with its subsidiaries, operates as a retailer and distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours. In addition, it operates online drugstore that retails OTC drugs and nutritional supplements, as well as sells products through third-party platforms. Further, the company distributes third-party pharmaceutical products primarily to trading companies, as well as cultivates and wholesales herbs used for TCM. As of March 31, 2021, it had 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores. The company was founded in 2003 and is headquartered in Hangzhou, the People's Republic of China.

Full CJJD Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this CJJD vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CJJD vs SCHDCJJD vs JEPICJJD vs OCJJD vs KOCJJD vs MAINCJJD vs HTGCCJJD vs GBDCCJJD vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.